MDxHealth

MDXHApproved

Founded 1999mdxhealth.com

MDxHealth is a Belgium-based, publicly traded company that develops and commercializes molecular diagnostic tests for urologic diseases, with a primary focus on prostate cancer. The company leverages proprietary genetic, epigenetic, and complex molecular technologies to offer a suite of tests that address key clinical decision points, from initial risk assessment to post-treatment monitoring. Having impacted over 500,000 patients, MDxHealth operates as a commercial-stage entity with tests like ConfirmMDx and GPS, and is expanding its menu with new additions like the ExoDx Prostate Test.

Market Cap

$162.3M

Founded

1999

Focus

Diagnostics

MDXH · Stock Price

USD 3.164.97 (-61.13%)

Historical price data

AI Company Overview

Technology Platform

Utilizes proprietary genetic, epigenetic, and complex molecular technologies to develop diagnostic tests, including analysis of DNA methylation, gene expression profiles, and urinary biomarkers (mRNA, exosomal RNA).

Funding History

Total raised: $65M

Debt$15MKreos CapitalSep 15, 2020

PIPE$20MUndisclosedMar 15, 2017

IPO$30MUndisclosedJun 15, 2011

Opportunities

Growth is driven by expanding the commercial footprint of its integrated prostate cancer test portfolio, particularly the new ExoDx test, and by demonstrating cost-effectiveness to secure broader insurance coverage.

The large addressable market in prostate cancer diagnostics and the need for solutions in antibiotic stewardship for UTIs present significant opportunities.

Risk Factors

Key risks include dependence on favorable and stable reimbursement from payers, intense competition in the molecular diagnostics space, the challenge of driving clinical adoption of multiple tests, and the financial execution required as a smaller public company to fund growth initiatives.

Competitive Landscape

MDxHealth competes with companies like Veracyte (Decipher), Myriad (Prolaris), and Bio-Techne/Exosome Diagnostics in prostate cancer genomics, and with molecular microbiology companies in UTI testing. Its differentiation lies in offering a comprehensive suite of tests covering the entire prostate cancer patient pathway, from initial suspicion to treatment guidance.